Quynh-Thu Le
Academic Appointments
- Professor - Med Center Line, Radiation Oncology - Radiation Therapy
- Member, Bio-X
- Member, Stanford Cancer Institute
- Professor - Med Center Line (By courtesy), Otolaryngology (Head and Neck Surgery)
Key Documents
Contact Information
-
Clinical Offices
Radiation Therapy 875 Blake Wilbur Dr Clinic D Stanford, CA 94305 Tel Work (650) 723-6171 Fax (650) 725-8231Practices at Stanford Hospital and Clinics and Lucile Packard Children's Hospital
- Academic Offices
Personal Information Email Tel (650) 498-5032Adminsitrative Contact Tiffany Symmes Executive Assistant Email Tel Work 650-725-0203Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Head and Neck Cancer
- Cancer> Radiation Oncology
- Lung Cancer - Radiation Oncology
- Salivary Gland Tumors - Radiation Oncology
- Head and Neck Cancers - Radiation Oncology
- Larynx Cancer - Radiation Oncology
Administrative Appointments
- Editorial Board, Practical Radiation Oncology (2011 - present)
- Chair, RTOG Head and neck Committee (2012 - present)
- Chair, Department of Radiation Oncology, Stanford University (2011 - present)
- Editorial Board, Journal of Clinical Oncology (2005 - 2009)
- IMRT Practicum Course Co-Director, American Society of Therapeutic Oncology and Radiology (2004 - 2009)
- Educational Committee Vice Chair, American Society of Therapeutic Radiology and Oncology (2005 - 2012)
Professional Education
| Internship: | Highland General Hospital - Alameda Co Medical Center CA (1994) |
| Board Certification: | Radiation Oncology, American Board of Radiology (1998) |
| Residency: | UCSF Medical Center CA (1997) |
| Medical Education: | UCSF School of Medicine CA (1993) |
| MD: | UCSF, Medicine (1993) |
Graduate & Fellowship Program Affiliations
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
My laboratory research interest focuses on the identification of biomarkers for prognosis in patients with head & neck or lung cancers. Current research goals are: to validate the prognostic significance of certain hypoxia markers using clinical samples from a randomized phase III clinical trial and to monitor the tumor burden of HPV-related head & neck cancers during therapy by tracking circulating HPV DNA in the blood. We are also looking to determine if plasma levels of MiR 210s can predict tumor hypoxia in head and neck cancers, to dissect the function of Osteopontin in tumor progression, to target Galectin-1 (an immunomodulator) in combination with radiation in solid tumors, and to identify a microRNA signature in lung cancer. Additionally we are working to isolate human salivary gland stem cells for salivary gland function rescue after head & neck radiation therapy.
I am also conducting a number of clinical trials specifically in patients with head and neck cancer. I am conducting a multi-site phase II study of Lapatinib plus radiation for head & neck cancer patients who cannot tolerate chemotherapy, and participating in several RTOG cooperative group studies for this disease site.
Clinical Trials
- Recruiting Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer
- Recruiting Imaging and Biomarkers of Hypoxia in Solid Tumors
- Recruiting Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer
- Not Recruiting Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer
- Not Recruiting TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.
Publications
- An international collaboration to harmonize the quantitative plasma epstein-barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res. 2013; (8): 2208-15
- Cost-effectiveness landscape analysis of treatments addressing xerostomia in patients receiving head and neck radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013
- Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. Cancer. 2013; (7): 1349-56
- Long-term outcomes of surgery followed by radiation therapy for minor salivary gland carcinomas. Laryngoscope. 2013
- Loss of the p53/p63 target PERP is an early event in oral carcinogenesis and correlates with higher rate of local relapse. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013; (1): 95-103
- Migration of implanted markers for image-guided lung tumor stereotactic ablative radiotherapy. J Appl Clin Med Phys. 2013; (2): 4046
Help